why choose us

300×250 Ad Slot

Drug FDA Status

Showing 50 of 158 result(s) (Page 5 of 16)
Drug Name: Tryptyr

Active Ingredient: acoltremon

Approval Date: 2025-05-28

Description: To treat the signs and symptoms of dry eye disease
Drug Trials Snapshot

Drug Name: Emrelis

Active Ingredient: telisotuzumab vedotin-tllv

Approval Date: 2025-05-14

Description: To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy 
Drug Trials Snapshot

Drug Name: Avmapki Fakzynja Co-Pack

Active Ingredient: avutometinib and defactinib

Approval Date: 2025-05-08

Description: To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
Drug Trials Snapshot

Drug Name: Imaavy

Active Ingredient: nipocalimab-aahu

Approval Date: 2025-04-29

Description: To treat generalized myasthenia gravis
Drug Trials Snapshot

Drug Name: penpulimab-kcqx

Active Ingredient: penpulimab-kcqx

Approval Date: 2025-04-23

Description: In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
Drug Trials Snapshot

Drug Name: Vanrafia

Active Ingredient: atrasentan

Approval Date: 2025-04-02

Description: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
Drug Trials Snapshot

Drug Name: Qfitlia

Active Ingredient: fitusiran

Approval Date: 2025-03-28

Description: To prevent or reduce the frequency of bleeding episodes in hemophilia A or B
Press Release
Drug Trials Snapshot

Drug Name: Blujepa

Active Ingredient: gepotidacin

Approval Date: 2025-03-25

Description: To treat uncomplicated urinary tract infections
Drug Trials Snapshot

Drug Name: Romvimza

Active Ingredient: vimseltinib

Approval Date: 2025-02-14

Description: To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity
Drug Trials Snapshot

Drug Name: Gomekli

Active Ingredient: mirdametinib

Approval Date: 2025-02-11

Description: To treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection 
Drug Trials Snapshot

300×250 Ad Slot